Baker Bros. Advisors’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-4,954,855
| Closed | -$605M | – | 107 |
|
|
2022
Q4 | $605M | Buy |
4,954,855
+102,200
| +2% | +$11.9M | 3.63% | 6 |
|
|
2022
Q3 | $501M | Hold |
4,852,655
| – | – | 3.28% | 6 |
|
|
2022
Q2 | $451M | Buy |
4,852,655
+311,051
| +7% | +$29.3M | 2.56% | 6 |
|
|
2022
Q1 | $533M | Hold |
4,541,604
| – | – | 3.06% | 6 |
|
|
2021
Q4 | $611M | Hold |
4,541,604
| – | – | 2.97% | 7 |
|
|
2021
Q3 | $724M | Buy |
4,541,604
+1,001,334
| +28% | +$137M | 3.18% | 5 |
|
|
2021
Q2 | $466M | Hold |
3,540,270
| – | – | 2.05% | 7 |
|
|
2021
Q1 | $456M | Hold |
3,540,270
| – | – | 1.98% | 9 |
|
|
2020
Q4 | $590M | Hold |
3,540,270
| – | – | 2.22% | 10 |
|
|
2020
Q3 | $546M | Buy |
3,540,270
+150,000
| +4% | +$21.6M | 2.18% | 8 |
|
|
2020
Q2 | $501M | Hold |
3,390,270
| – | – | 2.21% | 8 |
|
|
2020
Q1 | $382M | Hold |
3,390,270
| – | – | 2.35% | 8 |
|
|
2019
Q4 | $472M | Hold |
3,390,270
| – | – | 2.51% | 9 |
|
|
2019
Q3 | $327M | Hold |
3,390,270
| – | – | 2.22% | 9 |
|
|
2019
Q2 | $390M | Hold |
3,390,270
| – | – | 2.65% | 9 |
|
|
2019
Q1 | $399M | Buy |
3,390,270
+552,918
| +19% | +$48.4M | 2.55% | 9 |
|
|
2018
Q4 | $178M | Hold |
2,837,352
| – | – | 1.46% | 9 |
|
|
2018
Q3 | $201M | Hold |
2,837,352
| – | – | 1.32% | 10 |
|
|
2018
Q2 | $189M | Hold |
2,837,352
| – | – | 1.42% | 10 |
|
|
2018
Q1 | $186M | Buy |
2,837,352
+218,534
| +8% | +$12.3M | 1.57% | 8 |
|
|
2017
Q4 | $105M | Buy |
2,618,818
+269,978
| +11% | +$9.82M | 0.91% | 10 |
|
|
2017
Q3 | $85.1M | Buy |
2,348,840
+597,377
| +34% | +$17.1M | 0.69% | 12 |
|
|
2017
Q2 | $48.6M | Buy |
1,751,463
+400,000
| +30% | +$10.6M | 0.43% | 19 |
|
|
2017
Q1 | $37.8M | Buy |
1,351,463
+328,197
| +32% | +$8.29M | 0.31% | 25 |
|
|
2016
Q4 | $20.7M | Buy |
1,023,266
+277,745
| +37% | +$5.55M | 0.2% | 34 |
|
|
2016
Q3 | $15M | Hold |
745,521
| – | – | 0.14% | 44 |
|
|
2016
Q2 | $9.89M | Buy |
745,521
+240,000
| +47% | +$3.7M | 0.1% | 53 |
|
|
2016
Q1 | $9.38M | Hold |
505,521
| – | – | 0.1% | 58 |
|
|
2015
Q4 | $9.26M | Buy |
505,521
+69,981
| +16% | +$1.23M | 0.08% | 63 |
|
|
2015
Q3 | $7.71M | Buy |
435,540
+335,540
| +336% | +$6.53M | 0.07% | 67 |
|
|
2015
Q2 | $1.77M | Hold |
100,000
| – | – | 0.02% | 109 |
|
|
2015
Q1 | $1.74M | Buy |
+100,000
| New | +$1.82M | 0.01% | 109 |
|
Other funds holding ASND
RCM
ACA
Baker Bros. Advisors's ASND Position: Q1 2023 in Review
Baker Bros. Advisors sold out of Ascendis Pharma A/S (ASND) in Q1 2023, closing a stake of 4,954,855 shares — an estimated $605M sold.
Baker Bros. Advisors first reported a position in ASND in Q1 2015 and held it in 32 quarters. The position peaked at $724M in Q3 2021. 164 funds tracked by Wall St. Rank hold ASND as of Q1 2023.
- Baker Bros. Advisors reported no remaining Ascendis Pharma A/S position as of Q1 2023 after selling out during the quarter.
- Baker Bros. Advisors sold 4,954,855 Ascendis Pharma A/S shares in Q1 2023, an estimated $605M.
- Baker Bros. Advisors first reported a position in Ascendis Pharma A/S in Q1 2015 and held it in 32 quarters.
- Baker Bros. Advisors's Ascendis Pharma A/S position peaked at $724M in Q3 2021.
- 164 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2023.
Based on Baker Bros. Advisors's 13F filing for Q1 2023, filed 15 May 2023.